
## Enrique Roberto Soriano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8685693/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	2.9	726
2	Gait Velocity as a Single Predictor of Adverse Events in Healthy Seniors Aged 75 Years and Older. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1304-1309.	1.7	563
3	Treatment recommendations for psoriatic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1387-1394.	0.5	483
4	The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus. Medicine (United States), 2004, 83, 1-17.	0.4	372
5	Enthesitis: from pathophysiology to treatment. Nature Reviews Rheumatology, 2017, 13, 731-741.	3.5	316
6	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Annals of the Rheumatic Diseases, 2013, 72, 986-991.	0.5	240
7	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature Reviews Rheumatology, 2022, 18, 465-479.	3.5	182
8	Consensus on a core set of domains for psoriatic arthritis. Journal of Rheumatology, 2007, 34, 1167-70.	1.0	155
9	Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus, 2008, 17, 596-604.	0.8	108
10	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the Rheumatic Diseases, 2015, 74, 1019-1023.	0.5	100
11	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq1 1 0.</i>	784314 rg 0.5	gBT <sub>9</sub> Overlock
12	Diseases, 2018, 77, 1549-1557. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. Journal of Rheumatology, 2006, 33, 1422-30.	1.0	87
13	Patient Preferences for Biologic Agents in Rheumatoid Arthritis: A Discrete-Choice Experiment. Value in Health, 2013, 16, 385-393.	0.1	71
14	Early rheumatoid arthritis in Latin America: Low socioeconomic status related to high disease activity at baseline. Arthritis Care and Research, 2012, 64, 1135-1143.	1.5	65
15	Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus, 2009, 18, 1019-1025.	0.8	62
16	Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology, 2011, 50, 729-734.	0.9	62
17	Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 74-79.	0.5	55
18	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. Journal of Rheumatology, 2014, 41, 2277-2285.	1.0	51

#	Article	IF	CITATIONS
19	Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: Relevance of inflammation. Atherosclerosis, 2014, 237, 652-660.	0.4	47
20	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology, 2012, 51, 1293-1298.	0.9	46
21	Management of Patients With Rheumatoid Arthritis in Latin America. Journal of Clinical Rheumatology, 2009, 15, 203-210.	0.5	44
22	Ultrasound entheseal abnormalities at the distal interphalangeal joints and clinical nail involvement in patients with psoriasis and psoriatic arthritis, supporting the nail-enthesitis theory. Seminars in Arthritis and Rheumatism, 2017, 47, 338-342.	1.6	43
23	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. Arthritis Care and Research, 2019, 71, 1556-1565.	1.5	43
24	Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatology, 2021, 157, 43.	2.0	43
25	Ultrasound assessment of new onset bilateral painful shoulder in patients with polymyalgia rheumatica and rheumatoid arthritis. Clinical Rheumatology, 2012, 31, 1383-1387.	1.0	42
26	Remission criteria and activity indices in psoriatic arthritis. Clinical Rheumatology, 2014, 33, 1323-1330.	1.0	42
27	Treatment of Early Rheumatoid Arthritis in a Multinational Inception Cohort of Latin American Patients. Journal of Clinical Rheumatology, 2012, 18, 327-335.	0.5	41
28	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na¬ve or TNFα inhibitor-experienced. RMD Open, 2021, 7, e001457.	1.8	41
29	Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?. Lupus, 2015, 24, 788-795.	0.8	39
30	Effect of Education on Blood Pressure Control in Elderly PersonsA Randomized Controlled Trial. American Journal of Hypertension, 2006, 19, 737-743.	1.0	36
31	Value of repeat biopsy in lupus nephritis flares. Lupus Science and Medicine, 2014, 1, e000004.	1.1	35
32	Incidence and Prevalence of Systemic Sclerosis in a Healthcare Plan in Buenos Aires. Journal of Clinical Rheumatology, 2011, 17, 59-63.	0.5	32
33	Systemic Lupus Erythematosus and Amyloidosis. Arthritis and Rheumatism, 1979, 22, 554-556.	6.7	31
34	Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. Lupus Science and Medicine, 2014, 1, e000021.	1.1	31
35	Laparoscopic Colorectal Resections. Diseases of the Colon and Rectum, 2014, 57, 869-874.	0.7	29
36	Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis. Atherosclerosis, 2016, 251, 438-444.	0.4	29

#	Article	IF	CITATIONS
37	Incidence and Prevalence of Rheumatoid Arthritis in a Health Management Organization in Argentina: A 15-year Study. Journal of Rheumatology, 2016, 43, 1306-1311.	1.0	28
38	Gait disorders are associated with non-cardiovascular falls in elderly people: a preliminary study. BMC Geriatrics, 2005, 5, 15.	1.1	27
39	Incidence and Prevalence of Polymyositis and Dermatomyositis in a Health Management Organization in Buenos Aires. Journal of Clinical Rheumatology, 2013, 19, 303-307.	0.5	27
40	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. RMD Open, 2020, 6, e001097.	1.8	26
41	Health systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health. BMJ Global Health, 2021, 6, e006045.	2.0	26
42	REAL-PANLAR Project for the Implementation and Accreditation of Centers of Excellence in Rheumatoid Arthritis Throughout Latin America. Journal of Clinical Rheumatology, 2015, 21, 175-180.	0.5	25
43	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Research and Therapy, 2018, 20, 242.	1.6	24
44	Current status of the rheumatologists' workforce in Latin America: a PANLAR collaborative study. Clinical Rheumatology, 2021, 40, 2913-2920.	1.0	22
45	Body Surface Area. Diseases of the Colon and Rectum, 2012, 55, 1153-1159.	0.7	21
46	Prevalence and Correlates of Metabolic Syndrome in Patients With Rheumatoid Arthritis in Argentina. Journal of Clinical Rheumatology, 2013, 19, 439-443.	0.5	19
47	Utility of Power Doppler Ultrasound–detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission. Journal of Rheumatology, 2017, 44, 1018-1023.	1.0	19
48	Are superantigens the cause of cytokine storm and viral sepsis in severe COVIDâ€19? Observations and hypothesis. Scandinavian Journal of Immunology, 2020, 92, e12944.	1.3	19
49	OP0229â€THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021. Annals of the Rheumatic Diseases, 2021, 80, 139-140.	0.5	19
50	Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Rheumatology, 2008, 47, 1097-1099.	0.9	18
51	Incidence of multiple sclerosis in Buenos Aires: a 16â€year health maintenance organizationâ€based study. European Journal of Neurology, 2010, 17, 479-482.	1.7	18
52	Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. Rheumatology, 2013, 52, 510-514.	0.9	18
53	Proper management of rheumatoid arthritis in Latin America. What the guidelines say?. Clinical Rheumatology, 2015, 34, 51-55.	1.0	18
54	Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina. Rheumatology International, 2019, 39, 1697-1702.	1.5	18

#	Article	IF	CITATIONS
55	Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. Rheumatology International, 2022, 42, 41-49.	1.5	18
56	The Actual Role of Therapy with Traditional Disease-modifying Antirheumatic Drugs in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 67-70.	2.2	17
57	Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2017, 4, e000209.	1.1	17
58	CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study. Journal of Rheumatology, 2018, 45, 22-31.	1.0	17
59	New treatment paradigms in psoriatic arthritis. Current Opinion in Rheumatology, 2015, 27, 99-106.	2.0	16
60	Remission in psoriatic arthritis—where are we now?. Rheumatology, 2018, 57, 1321-1331.	0.9	16
61	Evaluation of Learned Helplessness, Perceived Self-efficacy, and Functional Capacity in Patients With Fibromyalgia and Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2019, 25, 65-68.	0.5	16
62	Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). RMD Open, 2020, 6, e001299.	1.8	16
63	Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model. Cost Effectiveness and Resource Allocation, 2011, 9, 4.	0.6	15
64	Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin. Journal of Rheumatology, 2016, 43, 907-910.	1.0	15
65	Rheumatoid Arthritis Patient's Journey. Journal of Clinical Rheumatology, 2020, 26, S148-S152.	0.5	15
66	FREQUENCY OF AUTOANTIBODIES TO A MAJOR EPITOPE ON THE CARBOXYL TERMINAL FRAGMENT OF CENP-B IN PATIENTS WITH AUTOIMMUNE DISEASE. Rheumatology, 1995, 34, 407-412.	0.9	14
67	Update on the treatment of peripheral arthritis in psoriatic arthritis. Current Rheumatology Reports, 2009, 11, 270-277.	2.1	14
68	Evaluation of learned helplessness, self-efficacy and disease activity, functional capacity and pain in Argentinian patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2017, 46, 17-21.	0.6	14
69	Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. Clinical Rheumatology, 2019, 38, 1935-1940.	1.0	14
70	Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric. Quality of Life Research, 2019, 28, 187-197.	1.5	14
71	Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. Clinical Rheumatology, 2020, 39, 1859-1869.	1.0	14
72	GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201681.	1.0	14

#	Article	IF	CITATIONS
73	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. Rheumatology and Therapy, 2021, 8, 1789-1808.	1.1	14
74	Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina. Clinical Rheumatology, 2015, 34, 929-933.	1.0	13
75	Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study. Rheumatology and Therapy, 2021, 8, 803-815.	1.1	13
76	Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice. BMC Musculoskeletal Disorders, 2016, 17, 110.	0.8	12
77	Impact of COVID-19 Pandemic on Rheumatology Practice in Latin America. Journal of Rheumatology, 2021, 48, 1616-1622.	1.0	12
78	GRAPPA Treatment Recommendations: Updates and Methods. Journal of Rheumatology, 2020, 96, 41-45.	1.0	12
79	GRAPPA Treatment Recommendations: 2021 Update. Journal of Rheumatology, 2022, , jrheum.211331.	1.0	12
80	Knee effusion: ultrasound as a useful tool for the detection of calcium pyrophosphate crystals. Clinical Rheumatology, 2016, 35, 1087-1091.	1.0	11
81	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Seminars in Arthritis and Rheumatism, 2017, 47, 199-203.	1.6	11
82	Effects of cigarette smoking on early arthritis: a cross-sectional study—data from the Argentine Consortium for Early Arthritis (CONAART). Rheumatology International, 2015, 35, 855-859.	1.5	10
83	Defining Remission in Psoriatic Arthritis: Are We Getting Closer?. Journal of Rheumatology, 2015, 42, 907-908.	1.0	10
84	Responsiveness to therapy change of a global ultrasound assessment in spondyloarthritis patients. Clinical Rheumatology, 2015, 34, 125-132.	1.0	10
85	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Clinical Rheumatology, 2019, 38, 2737-2746.	1.0	10
86	Ultrasound Evaluation of the Greater Trochanter Pain Syndrome. Journal of Clinical Rheumatology, 2015, 21, 99-101.	0.5	9
87	Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. Clinical Rheumatology, 2019, 38, 2211-2217.	1.0	9
88	PANLAR consensus statement on biosimilars. Clinical Rheumatology, 2019, 38, 1485-1496.	1.0	9
89	Consultations for work related low back pain in Argentina. Journal of Rheumatology, 2002, 29, 1029-33.	1.0	9
90	ANCA-associated pauci-immune glomerulonephritis: always pauci-immune?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 55-58.	0.4	9

#	Article	IF	CITATIONS
91	Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs. Best Practice and Research in Clinical Rheumatology, 2014, 28, 793-806.	1.4	8
92	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatology: Research and Reviews, 2016, 8, 37.	0.8	8
93	Does a Simplified 6-Joint Ultrasound Index Correlate Well Enough With the 28-Joint Disease Activity Score to Be Used in Clinical Practice?. Journal of Clinical Rheumatology, 2016, 22, 179-183.	0.5	8
94	Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus, 2017, 26, 73-83.	0.8	8
95	Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. Clinical Rheumatology, 2019, 38, 2129-2139.	1.0	8
96	Validation of a Prediction Rule for the Diagnosis of Rheumatoid Arthritis in Patients with Recent Onset Undifferentiated Arthritis. International Journal of Rheumatology, 2013, 2013, 1-6.	0.9	7
97	Therapeutic Guidelines for Latin American Lupus Patients. Journal of Clinical Rheumatology, 2018, 24, 41-44.	0.5	7
98	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 33-41.	0.8	7
99	A Consensus Position Paper From REAL-PANLAR Group About the Methodological Approach for the Accreditation Process of Centers of Excellence in Rheumatoid Arthritis in Latin America. Journal of Clinical Rheumatology, 2019, 25, 54-58.	0.5	7
100	Frequency and clinical associations of anti-chromo antibodies in connective tissue disease Annals of the Rheumatic Diseases, 1994, 53, 666-670.	0.5	6
101	Performance of Ultrasonography Compared to Conventional Radiography for the Diagnosis of Osteoarthritis in Patients With Knee Pain. Frontiers in Medicine, 2020, 7, 319.	1.2	6
102	Treatment guidelines for psoriatic arthritis. International Journal of Clinical Rheumatology, 2009, 4, 329-342.	0.3	5
103	Critical Appraisal of the Guidelines for the Management of Ankylosing Spondylitis: Disease-Modifying Antirheumatic Drugs. American Journal of the Medical Sciences, 2012, 343, 357-359.	0.4	5
104	Systematic and progressive implementation of the centers of excellence for rheumatoid arthritis: a methodological proposal. Clinical Rheumatology, 2017, 36, 2855-2858.	1.0	5
105	Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. Future Science OA, 2018, 4, FSO289.	0.9	5
106	Best-practice Indicators in Psoriatic Disease Care. Journal of Rheumatology, 2019, 95, 38-45.	1.0	5
107	Synovial tissue responses following treatment of rheumatoid arthritis with the humanized monoclonal antibody CAMPATH-1H. Arthritis and Rheumatism, 1996, 39, 181-182.	6.7	4
108	A case of primary erythromelalgia. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1338-1339.	1.3	4

#	Article	IF	CITATIONS
109	Management of Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 711-722.	0.8	4
110	The Value of Power Doppler Ultrasound in Patients With Rheumatoid Arthritis in Clinical Remission: Reclassifying Disease Activity?. ReumatologÃa ClÃnica (English Edition), 2018, 14, 202-206.	0.2	4
111	Interventions on Modifiable Risk Factors for the Development of Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2019, 5, 313-325.	0.6	4
112	Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Low Back Pain. Journal of Rheumatology, 2019, 46, 694-700.	1.0	4
113	Fragility fractures in psoriatic arthritis patients: a matched retrospective cohort study. Clinical Rheumatology, 2020, 39, 3685-3691.	1.0	4
114	Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. Clinical Rheumatology, 2020, 39, 1813-1822.	1.0	4
115	LARS study: Latin American rheumatologist survey. Clinical Rheumatology, 2021, 40, 377-387.	1.0	4
116	Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study. Advances in Rheumatology, 2021, 61, 21.	0.8	4
117	Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52ÂWeeks: Data from Three PhaseÂIII Randomised Controlled Trials. Advances in Therapy, 2022, 39, 2806-2819.	1.3	4
118	Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis. Medical Devices: Evidence and Research, 2010, 3, 25.	0.4	3
119	Design of an algorithm for the diagnostic approach of patients with joint pain. Clinical Rheumatology, 2021, 40, 1581-1591.	1.0	3
120	Rheumatology Training in Latin America. Journal of Clinical Rheumatology, 2022, 28, e440-e443.	0.5	3
121	Correspondence on â€~No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€~physician-reported spondylitis'?'. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.5	3
122	Inflammatory muscle disease: therapeutic aspects. Best Practice and Research in Clinical Rheumatology, 2000, 14, 55-71.	1.4	2
123	Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era. ClinicoEconomics and Outcomes Research, 2012, 4, 219.	0.7	2
124	Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?. International Journal of Rheumatology, 2014, 2014, 1-5.	0.9	2
125	Defining Quality of Rheumatolgic Care: Argentina. Journal of Clinical Rheumatology, 2017, 23, 207-208.	0.5	2
126	Valor de la ecografÃa con Doppler de poder en pacientes con artritis reumatoide en remisión clÃnica: ¿reclasificación de la actividad de la enfermedad?. ReumatologÃa ClÃnica, 2018, 14, 202-206.	0.2	2

#	Article	IF	CITATIONS
127	Psoriatic arthritis: new evidence for old concepts. Current Opinion in Rheumatology, 2018, 30, 87-93.	2.0	2
128	Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol. Value in Health Regional Issues, 2020, 21, 201-204.	0.5	2
129	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	0.8	2
130	AB1075â€Argentinian Register of BIOLOGICS Treatments (BIOBADASAR). Results. Annals of the Rheumatic Diseases, 2014, 73, 1156.3-1157.	0.5	1
131	AB0802â€Use of Caspar and ASAS Classification Criteria for Peripheral Involvement in Patients Diagnosed with Psoriatic Arthritis in the Region of Murcia (Spain). Annals of the Rheumatic Diseases, 2015, 74, 1167.3-1167.	0.5	1
132	SAT0427â€Asas health index: validity and reliability in argentinean patients with spondyloarthritis. , 2017, , .		1
133	FRI0709-HPRâ€Levels of satisfaction with psoriatic arthritis (PSA) treatment and associated alignment between rheumatologists and their patients across latin america. , 2018, , .		1
134	Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina. Lupus, 2019, 28, 1167-1173.	0.8	1
135	Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis. Dermatology, 2019, 235, 101-106.	0.9	1
136	Response to: â€~Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg. Annals of the Rheumatic Diseases, 2019, 78, e120-e120.	0.5	1
137	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	0.8	1
138	SAT0426â€CAN BIOLOGICS "PREVENT―THE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PSORIASIS PATIEN DATA FROM A LARGE UNIVERSITY HOSPITAL COHORT IN ARGENTINA. Annals of the Rheumatic Diseases, 2020, 79, 1167-1168.	NTS? 0.5	1
139	Ultrasound-detected tenosynovitis as a risk factor for flares in rheumatoid arthritis patients in clinical Rheumatology, 2022, , 1.	1.0	1
140	Re: Guidelines for the diagnosis and management of PMR/GCA. Age and Ageing, 2004, 33, 210-a-211.	0.7	0
141	Initial Application for Investigational Device Exemption (IDE). The Neuroradiology Journal, 2005, 18, 79-86.	0.1	0
142	BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS: A DISCRETE CHOICE EXPERIMENT. Value in Health, 2010, 13, A243.	0.1	0
143	Patient Considerations in the Management of Rheumatoid Arthritis: Role of Once-A-Month Golimumab Injection. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S3574.	0.4	0
144	CONVENTIONAL THERAPY OF PSORIATIC ARTHRITIS: EVIDENCE-BASED REVIEW. Reumatismo, 2011, 59, 81-4.	0.4	0

#	Article	IF	CITATIONS
145	THU0145â€Low Agreement Between Clinical Practice and Centralized Lecture Using the Sharp/Van DER Heijde Score in Patients with Early RA. Results from the Gladar Multinational Cohort. Annals of the Rheumatic Diseases, 2015, 74, 246.1-246.	0.5	0
146	SAT0123â€Radiographic Severity of Rheumatoid Arthritis in Latin American Patients: Results from The Gladar Cohort. Annals of the Rheumatic Diseases, 2016, 75, 709.3-710.	0.5	0
147	192â€Protective effect of antimalarials on the risk of damage accrual in systemic lupus erythematosus. , 2017, , .		0
148	AB0516â€Incidence of cancer in a cohort of patients with primary sjÃ−gren syndrome. , 2017, , .		0
149	FRI0483â€Work capacity and quality of life in a cohort of patients with early psoriatic arthritis in argentina. , 2017, , .		0
150	AB0194â€Journey of a patient with rheumatoid arthritis: delay in diagnosis and treatment. , 2017, , .		0
151	FRI0601â€Hyperferritinemic syndrome in a general universitary hospital. , 2017, , .		0
152	AB0789â€The psoriatic arthritis patient's journey: special emphasis on diagnosis and treatment delays. , 2017, , .		0
153	CS-08â€Effect of antimalarials over the different domains of the damage index in latin american SLE patients. , 2018, , .		0
154	FRI0099â€Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes. , 2018, , .		0
155	AB1228â€ACCESS TO RHEUMATOLOGIC TREATMENTS AND AUTOIMMUNE CONDITIONS IN LATIN AMERICA. , 2019, , .		0
156	Report on the Second PANLAR Review Course in Rheumatology. Journal of Clinical Rheumatology, 2020, 26, 33-36.	0.5	0
157	Improvement in the capacity of HDL to acquire free cholesterol associated with anti-inflammatory actions of tofacitinib in patients with RA. Atherosclerosis, 2020, 315, e152-e153.	0.4	0
158	Effectiveness of the use of an algorithm in the diagnostic approach of joint pain patients by primary care physicians. Rheumatology International, 2020, 40, 1857-1864.	1.5	0
159	POS0984â€PREVALENCE OF AXIAL SPONDYLOARTHRITIS AMONG YOUNG PEOPLE CONSULTING BECAUSE OF CHRONIC LOW BACK PAIN IN A UNIVERSITY HOSPITAL IN ARGENTINA. Annals of the Rheumatic Diseases, 2021, 80, 759-760.	0.5	0
160	POS1188â€COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTIN REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY) TJ ETQq		Øverlock I
161	POS0302â€BURNOUT IN RHEUMATOLOGISTS IN LATIN AMERICA. Annals of the Rheumatic Diseases, 2021, 80, 376.2-377.	0.5	0
162	AB0214â€SURVIVAL, EFFICACY AND SAFETY OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS: DATA FROM AN ARGENTINEAN COHORT. Annals of the Rheumatic Diseases, 2021, 80, 1133-1134.	0.5	0

#	Article	IF	CITATIONS
163	AB0529â€CHARACTERIZATION OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: POST-HOC ANALYSIS FROM TWO PHASE 3 TRIALS. Annals of the Rheumatic Diseases, 2021, 80, 1294-1295.	0.5	0
164	Oral Non-biologic Therapies and Non-pharmacological Therapies in PsA. , 2016, , 267-279.		0
165	THU0323â€Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis. , 2018, , .		0
166	SAT0345â€Quality indicators in the care of psoriatic arthritis. , 2018, , .		0
167	FRI0668â€Item response theory to standardize patient reported physical function outcomes; linking 10 commonly used questionnaires to a common metric. , 2018, , .		0
168	SAT0144â€DOES POLYPHARMACY IN RHEUMATOID ARTHRITIS PATIENTS AFFECT THE TREAT TO TARGET STRATEGY?. Annals of the Rheumatic Diseases, 2020, 79, 1010.1-1010.	0.5	0
169	AB0831â€COMPARISON OF DIFFERENT REMISSION INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM PHASE 3 TOFACITINIB STUDIES. Annals of the Rheumatic Diseases, 2020, 79, 1720-1721.	0.5	0
170	FRI0332â€EVALUATION OF THE INDIVIDUAL COMPONENTS OF ACR50+PASI100 AND MDA AT WEEK 24 FROM SPIRIT-H2H TRIAL COMPARING THE EFFICACY AND SAFETY OF IXE VERSUS ADA IN PATIENTS WITH PSA NAÃVE TO BDMARDS. Annals of the Rheumatic Diseases, 2020, 79, 758.1-758.	THE 0.5	0
171	AB1270â€RHEUMATOLOGY WORKFORCE IN LATIN AMERICA: TRAINING AND CURRENT STATUS. Annals of the Rheumatic Diseases, 2020, 79, 1926.1-1926.	0.5	0
172	Cambios en la función endotelial vascular de pacientes con artritis reumatoidea en tratamiento. Global Rheumatology, 0, , .	0.0	0
173	Evaluación de las necesidades educativas en pacientes con osteoartritis de rodilla en una cohorte latinoamericana. Global Rheumatology, 0, , .	0.0	0
174	Current Status and Future Challenges in the Treatment of Rheumatic Diseases. Frontiers in Drug Safety and Regulation, 2022, 2, .	0.5	0